+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study



Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study



Journal of Clinical Psychopharmacology 15(4 Suppl 2): 24s-30s



In a double-blind, randomized, controlled, multicenter clinical trial in general practice, lasting 7 weeks, a fixed dose of moclobemide (400 mg daily) was compared with a fixed dose of clomipramine (150 mg daily). A total of 147 patients with DSM-III-R major depression were included in the study. After a 1-week drug-free washout period, patients were stratified, according to total scores on the Hamilton Rating Scale for Depression (HAM-D), into two groups-HAM-D total scores, 11 to 15 points, and HAM-D total scores, 16 points or more. A comparison of the therapeutic effect of the two treatments was based on HAM-D total scores and the classification of patients into therapeutic response categories defined on the basis of total rating score, complete response, HAM-D ltoreq 7 points; partial response, HAM-D, 8 to 15 points; or no response, HAM-D gtoreq 16 points. The Newcastle Diagnostic Rating Scale (1965) was used to classify the patients into two groups, endogenous and nonendogenous. Adverse events were registered by use of the UKU side effect scale. Clinical global assessments of severity, efficacy, and tolerance were completed during the active treatment period. Compliance to treatment was based on levels of the drugs in plasma and the number of returned capsules. One hundred forty-two patients were evaluated for clinical effects. The results of the efficacy analyses showed therapeutic equivalence between moclobemide and clomipramine. There were no differences in the outcome of the two treatment groups or the two diagnostic groups (endogenous and nonendogenous). Treatment with clomipramine resulted in a higher dropout rate (40%), mostly as the result of adverse events and a statistically higher frequency of side effects (p lt 0.05); clomipramine was also significantly less tolerated than moclobemide (p lt 0.0001). Important differences were found in the clinical characteristics between the included patients and a similar patient sample from an inpatient study; these clinical characteristics explained some of the differences in the conclusions of the trials with moclobemide and other new antidepressants.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009029914

Download citation: RISBibTeXText

PMID: 7593726


Related references

A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. International Clinical Psychopharmacology 7(3-4): 159-165, 1993

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression. European Neuropsychopharmacology 10(Suppl. 3): S249, 2000

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 76(1-3): 191-200, 2003

A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatrica Scandinavica 92(2): 125-131, 1995

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry 55(7): 301-305, 1994

Moclobemide (Ro 11-1163) vs. clomipramine in the treatment of depression: A double-blind multicenter study in Belgium. Drug Development Research 21(4): 325-331, 1990

Moclobemide ro 11 1163 vs. clomipramine in the treatment of depression a double blind multicenter study in belgium. Drug Development Research 21(4): 325-332, 1990

Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study. International Clinical Psychopharmacology 7(3-4): 141-147, 1993

Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 42(1): 22-29, 2003

Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. Journal of the American Academy of Child & Adolescent Psychiatry 42(1): 22-29, 2003

Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. Applied Animal Behaviour Science 67(4): 255-275, 2000

A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatrica Scandinavica. Supplementum 350: 132-134, 1989

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. British Journal of Psychiatry 160: 519-524, 1992

Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 50-51, 1990

Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 34(3): 96-103, 2001